Oxygen: Friend or Foe?

Shout out to Chelsea Jorgenson, nurse at UW Medical Center, for the episode idea! 

Oxygen is a drug.

The FDA regulates medical gases like oxygen as a drug, with the approved indications of hypoxia and hypoxemia. Did you know these are different?

  • Hypoxemia: reduced partial pressure of O2 in the blood (low PaO2).

  • Hypoxia: reduced tissue levels of O2 so that cellular metabolism is impaired.

    • Hypoxemia generally precedes hypoxia. 

      • You have less oxygen to deliver, so there’s less O2 in the tissues over time. 

    • Hypoxemia does not always result in hypoxia

      • For instance, those who live at high altitude can by hypoxemic, but not hypoxic. 

Like other drugs, oxygen has benefits, but also has potential harms. And for a quick review of the benefits/harms of oxygen medically, check out the Journal of Hospital Medicine’s series, “Things We Do For No Reason.”

Many studies have shown, mostly on animal models, that hyperoxygenation leads to lung injury, inflammation through free radical generation, and changes in perfusion that may actually be harmful:

    • COPD: oxygen titrated to goal >88-92% is associated with 2x fold increased mortality risk.

      • Linked likely due to worsened ventilation-perfusion matching and poorer CO2 offloading as PaO2 rises (Haldane effect). 

    • MI: 1976 RCT of O2 in suspected MI patients at 6L/min. Patients receiving for 24 hours or more had more episodes of tachycardia with no improvement in mortality, analgesic use, or infarct size. 

      • Subsequent trials have found similar outcomes, and actually have also demonstrated increased rate of MI recurrence with O2 use.

      • European Society of Cardiology has now actually recommended no O2 use unless SpO2 < 90% for MI patients! 

    • Retinopathy of prematurity: hyper oxygenation of neonates increases risk of blindness.

    • Other illness: trials in settings ranging from ICUs, strokes, TBIs, and cardiac arrest have also linked liberal O2 use (ranging from 2L NC upwards) to increased mortality and other adverse events.

      • A meta analysis demonstrated a dose-dependent toxicity: for every 1% increase of SpO2 above 94-96%, there was 25% relative increase in in hospital mortality!!! 

So when is oxygen helpful?

Importantly, these studies have mostly looked at normoxemic patients who receive supplemental oxygen. Patients who are significantly hypoxemic or hypoxic will certainly benefit from O2. 

Additionally, patients with conditions such as CO poisoning, cluster headaches, sickle cell crisis, and pneumothorax may all benefit from O2. These are actual indications for the drug.

OK, so what about pregnancy and labor?

O2 is most commonly administered in labor, in an attempt to improve fetal status. The thought being that, if we see significant decelerations that reflect fetal hypoxia, administration of supplemental oxygen through the mother/placenta will help to correct it. 

  • Pro oxygen evidence:

    • Fetal pulse oximetry studies 2 small studies using a fetal pulse-oximeter in laboring women demonstrated increased fetal oxygenation of 5% with simple face masks, and 7-15% when using non-rebreathers, in non-hypoxic fetuses. In hypoxic fetuses, the observed benefit was greater, 20% with simple face mask and 26-37% with non-rebreather. 

      • Fetal pulse oximetry did not help to improve rates of cesarean delivery for fetal indications, and thus has not caught on as a routine technology in labor management. Thus critics would argue it’s hard to interpret these studies in context of whether O2 improves neonatal outcomes, or just makes the saturation numbers better.

  • Anti-oxygen evidence:

    •  Fetal scalp pH study:a small study examining the effect of administering 50-10% oxygen during first stage of labor actually had no effect on fetal scalp pH, and trended towards a worsening base deficit with supplemental O2. Another study of primates administered O2 with acidotic fetuses by scalp pH demonstrated worsening of acidosis with O2 administration. 

      • These studies though, like the others, were small and nonrandomized. There is also criticism in the timing and application of O2 in each of these trials. 

    • Non-inferiority RCT: a 2018 RCT in JAMA used a non-inferiority approach to randomize 114 patients to supplemental O2 versus room air with category II EFM. They found no difference between groups in improving umbilical artery lactate, which was their primary marker for this trial.

      • There was also no difference in other cord gas components or rates of cesarean delivery for fetal indications. 

      • Umbilical artery lactate does have some ability to predict hypoxia-associated morbidity in neonates; however, it is not sensitive or specific for poor outcomes, a valid criticism. The trial was not powered for neonatal outcomes. 

    • A secondary analysis of this same RCT looked at umbilical venous O2 concentration and actually found lower O2 pressure in fetuses exposed to long periods of O2 than those exposed for short periods or on room air. 

The physiologic arguments for (or against) O2

Check out our fetal circulation episode for a quick review of how blood and oxygen travel in the fetus!

The maximum fetal PO2 (i.e., in the umbilical vein at the site of the placenta) cannot exceed maternal venous PO2. This is why fetal hemoglobin has to have a very high oxygen affinity, as it must extract O2 away from the venous side of maternal blood, which already is at a lower oxygen concentration. 

An oxygen dissociation curve. Fetal hemoglobin maintains relatively excellent saturations, even at usual venous O2 pressures in maternal circulation (HbA). Source: WIKIPEDIA.

  • A normal venous Po2 in adults is around 35-45 mmHg (arterial is around 100 mmHg). That would equate on a HbA dissociation curve to a saturation of around 65-75%. 

  • A normal Po2 in a venous cord gas, by comparison, is on average around 35mmHg, again representing maternal venous O2 tension. 

    • But the fetal hemoglobin affinity for O2 powers this to about an 80-90% saturation! And that is considered normal -- most O2 saturation values at the 5 minute Apgar are in the mid-80%s.

  • The question lies herein: by causing maternal hyperoxemia, will that result in fetal recovery if the fetus is hypoxic? 

    • By increasing the PaO2 in the mother with supplemental oxygen, theoretically there would be an increased oxygen gradient to diffuse downstream to the fetus. 

      • In effect, because there is more oxygen tension, the higher the maternal PvO2 and umbilical vein O2 pressure can become.

    • But as we discussed with ischemic events, sometimes oxygen may counterintuitively not improve outcomes, or mask worsening of the process! 

      • In this case, the fetus becomes hypoxic, or the “ischemic” tissue -- would the new O2 load in this case be detrimental? 

      • Or potentially, like in COPD, would the normoxemia actually mask worsening acidosis? 

      • Or finally, as demonstrated in the RCT we referenced, does the O2 even get to the fetus due to some placental transfer failure in the presence of hyperoxia?

What should the bottom line takeaway be?

That’s the other interesting thing about this -- in spite of the fact that there is little evidence supporting this practice, O2 is wildly popular as a resuscitative effort. It’s simple and quick to apply. 

Intrauterine resuscitation, defined as repositioning, oxytocin discontinuation, fluid administration, amnioinfusion, or oxygen administration in response to fetal heart rate tracing abnormalities, are all options. 

While we couldn’t identify any studies that shared the “natural history” of what’s done during a deceleration, anecdotally we know that reflexively, reaching for the facemask oftentimes will precede these other measures, despite the evidence on decelerations favoring these other options. In short, leave O2 for maternal hypoxia, or as a last-resort option for fetal resuscitation! 

Mastalgia

Mastalgia is breast pain. It’s a super common complaint, but one that we don’t spend a lot of time learning about in OB/GYN residency.  But a systematic approach and knowing a little bit of evidence makes this an easier problem to tackle!

There are 3 types of breast pain: cyclical, noncyclical, and extramammary 

Cyclical 

  • Characterizes about ⅔ of patients with mastalgia.

  • Associated with hormonal fluctuations of menstrual cycles, usually starts about a week prior to menses.

  • Usually bilateral, most severe in upper outer quadrants.

  • Caused by stimulation of ductal elements by estrogen.

  • Can also be associated with pharmacologic hormonal agents (ie. OCPs, HRT).

Noncyclical 

  • Represents ⅓ of women with true mastalgia.

  • Does not follow a menstrual pattern.

  • More likely to be unilateral or located in one position on a breast, etc. 

  • Causes are highly variable:

    • Large, pendulous breasts;

    • Diet and lifestyle (high fat diet, smoking, caffeine intake);

    • Breast cysts; ductal ectasia (meaning distention of subareolar ducts due to inflammation unrelated to infection);

    • Mastitis;

    • Inflammatory breast cancer;

    • Hidradenitis suppurativa;

    • Mondor’s disease (thrombophlebitis of the breast);

    • Trauma;

    • Certain medications, such as some SSRIs and antipsychotics, as well as spironolactone.

Extramammary - not a “true mastalgia.” 

  • Basically referred pain from the intercostal nerves, or chest wall pain likely due to muscular injury.

How common is mastalgia, and what are risk factors? 

  • Very common - up to 70% of women in the US will experience some type of mastalgia in their life.

  • Those at higher risk are older women, those with larger breast size, less fit and/or physically active.

How do you approach the evaluation of mastalgia? 

  1. History characterizing questions are super important with mastalgia! They can help to elicit the differences commonly seen between the cyclical and non-cyclical types, as well as find other potential causes of pain that are not true mastalgia.  

    • Where is the pain? Is it bilateral or just on one side? 

    • What does the pain feel like? Aching? Pinching? 

    • When does the pain occur? Does it occur around your period? 

    • Do you take any hormonal medications? 

    • Is it associated with other types of pain, like neck, back or shoulder pain? 

    • Have you had a fevers/chills/systemic symptoms? 

    • Have you had any recent trauma to the chest? 

    • Does the pain affect daily function? 

    • Complete medical, surgical history etc. 

  2. Physical the breast exam can help to rule out any obvious causes, such as infection, mass or malignancy.

    • Examine for evidence of malignancy: mass, skin changes, or bloody nipple discharge.

    • Make sure you examine all 4 quadrants of the breast as well as the chest wall.

    • May have to have the patient lay on their side to be able to examine the chest wall when the breast falls away from the chest wall.

  3. Imaging/Labs Imaging is not always necessary, but can be in the right circumstances:

  • If mass, skin changes, bloody nipple discharge → mammography with or without ultrasound.

  • If no suspicious findings, may not necessarily need imaging, but will depend on presentation as well as if they are due for annual screening anyway.

  • Chance of having breast cancer with no abnormality on physical exam or imaging is about 0.5%. 

How do you treat mastalgia? 

  • Reassurance

    • Many times, women just want to know that their breast pain is normal and that they do not have breast cancer!

    • Studies have demonstrated this will be enough to satisfy 78-85% of women with normal findings.

    • Approximately 15% of women will need some other kind of treatment.

  • First line therapies

    • Physical support - well-fitting bra for support, warm compress or ice packs or gentle massage.

    • Over the counter analgesics - Tylenol, NSAIDs; topical NSAIds may also be useful.

    • Change in or cessation of hormonal medications 

  • Second line - if still having debilitating breast pain after first line treatments:

    • Tamoxifen - 10 or 20 mg daily, but can be associated with vasomotor symptoms of menopause.

    • Danazol - only FDA-approved treatment for mastalgia (fibrocystic breast disease) - usually around 200 mg daily.

      • Can be androgenizing, so avoid if planning pregnancy.

      • Rare hepatotoxicity with large doses (>400mg).

  • Other therapies not proven by randomized trial data:

    • Lifestyle changes (weight loss, stopping caffeine, low fat diet - 15% fat).

    • Evening primrose oil.

    • Vitamin E.

      • Many of these are offered and available over the counter, and have not demonstrated evidence of harm, either! So they may still be useful in your anti-mastalgia arsenal.





Benign Vulvar Dermatoses

So back in December 2019 (episode 66), we talked about vulvovaginal itching and gave a broad differential for workup of this very common symptom. Today, we thought we might focus on a few of the commonly tested and supremely confusing vulvar dermatoses, based on the new ACOG PB 224.

A quick refresher on diagnosis and workup: 

  • History and physical are supreme in helping you establish acute vs. chronic and narrowing down most likely suspects.

  • Labs beyond a wet mount are usually not needed, unless suspecting immunocompromise or needing a genital culture for persistent vaginitis symptoms.

  • Biopsies in general are reserved for ruling out possible premalignant or malignant areas.

Lichen Simplex Chronicus (LSC)

  • Chronic, nonscarring, inflammatory condition characterized by intense itch-scratch.

    • Most commonly reported symptom is chronic or intermittent intense itch, most commonly in the evening or night.

  • Very common - accounting for up to a third of vulvar clinic visits, and often is a secondary condition of other “itchy” vulvar disease like contact dermatitis. 

  • Most commonly encountered in middle aged women or elderly, and in women with a history of environmental allergies, asthma, or childhood eczema.

  • On exam, appearance is often erythematous, scaling, and/or lichenified (thickened/leathery) plaques, with variable degrees of excoriation due to the intense itching associated with the condition. 

    • The skin with longstanding disease is often described as “bark-like” it’s so thick! 

  • Consideration can be given to identifying other diseases that may be contributing to itching, such as candidiasis, but biopsy is not generally indicated.

  • Treatment is multipronged:

    • Education on stopping the itch-scratch cycle.

    • Removal of offending/worsening factors, such as contact dermatitis, excessive heat/moisture, or treatment of infection.

    • Medium or high-potency topical corticosteroid, applied once or twice daily. If started on steroid, should be seen again within 4 weeks to assess response and adjust course. 

    • Oral anti-pruritic medications.

Lichen Sclerosus

  • Chronic, scarring disorder that is bimodal in age distribution -- affects most commonly the anogential skin of prepubertal girls and postmenopausal women. 

  • Often asymptomatic and goes unrecognized by many clinicians.

  • If symptomatic, most common presenting symptoms include itching/irritation/burning, dyspareunia, and tearing.

  • On exam, the skin often has the classic “cigarette paper” appearance - thin, whitened, and crinkled. 

    • Extensive involvement from the superior vulva to the perianal tissue may create an “hourglass shape” of involvement which is classic for this disease.

    • Due to the scarring nature of the condition, the introitus may be narrowed, there may be phimosis (inability to retract skin around) of the clitoral hood, and presence of fissures. 

  • Biopsy is generally warranted in postmenopausal patients - patients with LS have increased risk of vulvar squamous cell carcinoma, ranging from 2-5%. 

    • Biopsy should be undertaken in areas which appear to be high risk -- i.e., if presence of any ulcers/erosions, or hyperpigmented or hyperkeratotic areas.

  • Treatment of LS is important in order to halt and prevent further scarring. Initially, a high potency corticosteroid should be used, generally clobetasol propionate 0.05% or mometasone furoate 0.1%. 

    • Dosing / application schedule is not well studied, but the PB recommends nightly for 4 weeks, every other night for 4 weeks, and then twice weekly for 4 weeks.

    • Maintenance therapy is generally needed until puberty in girls, or lifelong in older patients, and should be the most infrequent dosing that maintains resolution. 

    • For disease not responding to steroids, it is most important to ensure the diagnosis is correct! You don’t want to treat VIN/ vulvar SCC with steroids. 

      • Intralesional steroid injections or topical calcineurin inhibitors such as tacrolimus can be used for particularly resistant disease, but consider vulvar specialist referral before you are doing these.

Lichen Planus

  • Multisystem scarring dermatosis affecting the skin, oral mucosa, and vulvovaginal area, likely as a consequence of a dysfunctional cell-mediated immune system. 

    • Autoimmune disorders have been seen in up to a third of patients with LP.

  • Rare, with incidence in general population less than 1%. 

  • Most common in perimenopausal and menopausal women. 

  • Common presenting symptoms are dyspareunia, burning, soreness, itching, and vaginal discharge.

  • Diagnosis is complicated as there are multiple potential presentations; However, over 70% with vulvovaginal disease will also have oral involvement, so if suspected an oral exam should also be performed. 

    • Classic (papulosquamous): white, reticular, lacy, fernlike striae.

      • Dusty pink, poorly demarcated papules may also be present.

      • Occasionally with extensive involvement can “white out” vulvar skin and make picture confusing versus lichen sclerosus.

    • Erosive deep, painful, and erythematous lesions appear in posterior vestibule extending to labia minora. Architecture is often distorted and vaginal epithelium may be completely denuded. Lesions are extremely friable. 

    • Hypertrophic is the least common presentation, though with white, thick, warty plaques. 

  • Wet mount performed for diagnosis will often demonstrate an abundance of immune cells in addition to parabasal and basal epithelium, as well as increased pH (5-6)

  • Biopsy may be indicated based on the presentation, and may be helpful for distinguishing from rarer diagnosis like bullous pemphigoid / pemphigus vulgaris (ask your derm friends).

  • Treatment is based on expert opinion but is high-potency topical corticosteroids, generally twice daily and tapered back over time. 

    • For erosive disease, also should be treated with intravaginal steroid therapy, such as hydrocortisone suppositories, and followed by vulvar specialist. 

    • Often will also need dilator therapy along with steroids due to scarring nature of disease. 

A quick word on topical corticosteroids

  • So medium and high-potency corticosteroids feature heavily in the treatment of benign vulvar dermatoses… so review PB 224 for a list of them! 

    • Ointments are the preferred treatment compared to creams, lotions, or gels, as the ointments have the least additional additives that can make skin more sensitive and also allow for highest effective dose to penetrate the skin. 

ACOG PB 224

Perinatal Depression

Depression is a major health disorder affecting around 10% of women, particularly in the perinatal and postpartum periods. Depression is twice as common in women as in men, and OB/GYNs should be familiar with its diagnosis and management, particularly in the perinatal period. You can read more with ACOG CO 757.

There are many different types of depression diagnoses, including: major depressive disorder, persistent depressive disorder, seasonal affective disorder, perinatal (postpartum) depression, premenstrual dysphoric disorder (PMDD), etc. According to the DSM-V, a major depressive episode is diagnosed when one has: 

  • Five (or more) of the following symptoms have been present for a 2-week period and represent a change from previous functioning; at least one of the symptoms is either depressed mood or loss of interest/pleasure

  • Symptoms cannot be explained by medications or another medical illness (i.e., hypothyroidism).

  • The remaining (need 4+ from this list):

    • Depressed most of the day, nearly every day as indicated by subjective report or observation made by others;

    • Diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day;

    • Significant weight loss when not dieting or weight gain, or increase/decrease in appetite nearly every day;

    • Insomnia or hypersomnia;

    • Psychomotor agitation or retardation; 

    • Fatigue or loss of energy;

    • Feelings of worthlessness or inappropriate guilt;

    • Decreased ability to think/concentrate;

    • Recurrent thoughts of death/suicidal ideation.

Perinatal depression is defined separately as major and minor depressive episodes that occur during pregnancy or in the first 12 months after delivery. This is one of the most common medical complications during pregnancy and the postpartum period, affecting 1/7 women. 

Depression and other mood disorders can have devastating effects on women and their families: maternal suicide exceeds hemorrhage and hypertensive disorders as a cause of maternal mortality 

SO how do we screen for perinatal depression? ACOG recommends that obstetric care providers screen patients at least once during the perinatal period for depression and anxiety symptoms using a standardized tool, and again in the postpartum period during a comprehensive postpartum visit. There is evidence that screening alone can have clinical benefits for patients suffering with depression.

One of the most commonly used is the Edinburgh Postnatal Depression Screen, which is a 10 item survey that takes less than 5 minutes to complete. The sensitivity is estimated between: 59-100%, and specificity: 49-100%. A Spanish version is available.

The Patient Health Questionnaire 9 (PHQ-9) is another acceptable tool. Other items like the Postpartum Depression Screening Scale (PDSS) is more sensitive (91-94%) and specific (72-98%), but it is a 35 item survey and thus more time intensive.

Management of perinatal depression is a team sport, requiring multiple additional support members and medical team members. Medication prescription will vary for OB/GYNs and their comfort with this. In brief:

  • Women with current depression/anxiety or a history of perinatal mood disorder should have close monitoring, evaluation, and assessment.

  • Some OB/GYNs are comfortable starting antidepressant medication and following their patients, most commonly an SSRI. Psychiatry referral is also acceptable.

  • Referral to social work and behavioral health - possibly for psychotherapy, which alone is a reasonable alternative to antidepressants if needed.

  • For those with severe postpartum depression, another possibility is brexanolone.

    • Limited clinical experience and restricted availability 

    • Usually restricted to patients who do not improve with antidepressants 


Malposition and Malpresentation

We start off today with some news — for the foreseeable future, CREOGs Over Coffee will move to every-other-week Sunday episodes. It’s been a wild ride and now that we’ve moved across the country from each other, we want to make sure we deliver the same high-quality content we expect and want you to have! While you may hear less of us for now, we’re also working on some other projects, so stay tuned!

On to the episode! And for further reading, check out this review.

Malposition vs. Malpresentation

Fetal lie: the relationship between the fetal long axis and the mother (i.e., longitudinal, transverse, oblique).

Malpresentation: the fetal vertex is not the presenting part, or the part of the fetus closest to the pelvic inlet.

  • Breech: 3-4/100 term pregnancies

  • Face: 1/600-800 term deliveries

  • Brow: 1/500-4000 term deliveries

  • Compound: 1/1500 deliveries

  • Shoulder: 1/200 deliveries

Malposition: the fetus is in vertex position, but the position of the fetal head is not optimal for delivery (i.e., rotated away from an occiput anterior, or OA, position in the pelvis).

  • Occiput transverse (OT) or occiput posterior (OP).

    • These are given a direction based on rotation of the occiput 45 degrees from the direct position (i.e., right occiput posterior denotes rotation of the occiput to maternal right).

      • If occiput < 45 degrees from vertical, is OA or OP.

      • If occiput is > 45 degrees from vertical, is OT.

  • Prior to labor, 15-20% of term fetuses in cephalic presentation are in OP position. At delivery, only 5% will persist this way, as they will often rotate spontaneously.

Action to take with various malpositions and malpresentations:

First, a word on “normal” vaginal deliveries 

  • In OA position, the neck flexes to bring the chin to the chest → smaller diameter of the fetal head (about 9.5 cm), which is usually able to traverse the obstetric conjugate (average 10.5cm), which is the shortest anteroposterior pelvic diameter.

    • In other positions (ie. face or brow), the neck is extended and there is larger fetal cephalic head diameter that needs to traverse this area, making it more difficult to pass.

Breech, Transverse Lie, & Shoulder Presenations

  • We have previously discussed breech vaginal delivery, but current recommendation for breech and shoulder presentation is cesarean section.

  • Shoulder presentations cannot deliver vaginally. The shoulder is wedged into the pelvis, and the head will lie in one of the iliac fossa, and the breech in the other - the baby becomes wedged into the pelvic inlet and cannot get past.

  • For shoulder, describe using location of the scapula: 

    • Left scapula anterior (LSA), and RSA. 

    • Left scapula posterior (LSP), and RSP. 

  • With transverse lies, just like breech, can offer ECV prior to labor, but once labor occurs, usually versions become very difficult to do.

Face Presentation

  • The fetal face from forehead to chin is the leading fetal body part descending into the birth canal. This is usually diagnosed by vaginal exam (can palpate the orbital ridge, nose, mouth, chin), not able to palpate the fontanelles.

  • Described using location of the chin, or mentum.

    • At diagnosis, about 60% are mentum anterior and 26% are mentum posterior (ie. chin up or chin down); 15% are mentum transverse.

  • Management varies depending on presentation:

    • Mentum anterior The fetal chin needs to pass under the symphysis pubis, and fetal neck may need to extend even more (though it is already extended).

      • After the chin clears the symphysis, it is possible for vaginal delivery, and women should be allowed to push during second stage.

      • Forceps can be used, but engagement doesn’t occur until the face is at +2 station, and the chin, rather than the occiput becomes the focal point for orientation.

      • Vacuums are contraindicated… because where would you put it?!?!

    • Mentum posterior In this case, the fetal neck is maximally extended and cannot extend further to allow the occiput to pass under the symphysis.

      • Will NOT deliver vaginally unless there is spontaneous rotation to mentum anterior. 

      • If discovered early in labor, can have expectant management in the hopes that the mentum will spontaneously rotate to anterior.

      • However, recommendation is for cesarean if persistent mentum posterior with abnormal labor progress.

      • What about attempting rotation? 

        • Not a lot of cases, and there have been case reports of successful internal and external manipulation.

        • Some case reports of uterine rupture, cord prolapse, and cervical spine trauma.

        • Overall: if cesarean is available, would favor cesarean.

Brow presentation

  • A variant of face presentation, when presenting part is the anterior fontanelle to the brow (orbital ridge), which does not include the mouth and chin.

  • Diagnosis is usually made with vaginal exam (you can feel the forehead, orbits, and nose).

  • Management:

    • Can undergo trial of labor, as brow presentation may be transitional 

      • In one study, when brow presentation was diagnosed early, 67-75% of fetuses spontaneously converted to a more favorable presentation and delivered vaginally.

      • If diagnosed later:

        • 50% spontaneously converted and delivered;

        • 30% the neck extended further;

        • 20% the neck flexed and resulted in occiput posterior presentation. 

    • Rotational maneuvers, vacuum, and forceps are not recommended. 

Persistent occiput posterior 

  • Most common malposition, encountered very frequently in clinical practice, and will often convert spontaneously.

  • Manage expectantly in first stage of labor. In second stage of labor can also be expectant as long as fetal heart rate is reassuring and labor is progressing 

    • 50-80% of OP fetuses at beginning of second stage will rotate spontaneously to OA. 

    • If clinically adequate pelvis with a prolonged second stage - can attempt manual rotation to the OA position.

    • Prospective study - manual rotation vs. Expectant management of OP demonstrated higher likelihood of vaginal delivery and fewer cases of persistent OP presentation.

  • Manual rotation techniques 

    • Digital - placing tips of index and middle fingers in the anterior segment of the lamboid suture near the posterior fontanelle, and then used to flex and slightly dislodge the head, and rotation to OA position with the operator’s hand and forearm.

    • Hand - placing operator’s four fingers behind the posterior parietal bone with palm up and thumb over the anterior parietal bone. Right hand for LOP, left hand for ROP.

      • Flex and slightly dislodge the head → rotate.